glp 1r retatrutide Retatrutide—A Game Changer in Obesity Pharmacotherapy Dual and Triple Gut Peptide

And a clinical trial called Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) showed that Wegovy can significantly reduce the risk of major heart events in people with extra weight and a cardiovascular condition who dont have diabetes

P.BrownG

Yan W, Ma X, Gao X, Zhang S

You may be a good candidate if you are an adult with Type 2 diabetes who also has one of the following: Heart disease or multiple risk factors for heart disease Chronic kidney disease A body mass index (BMI) over 27 ( This means your weight is generally higher than whats considered healthy for your height .) For weight management, you may be a good candidate if you are an adult with: A BMI over 30 A BMI over 27 with one weight-related condition, such as: High blood pressure High cholesterol Type 2 diabetes Q: Who should not take a GLP-1 medication

DoW SBIR/STTR BAAs and CSOs are published at two sites